|Articles|January 15, 2002
- BioPharm International-01-01-2002
- Volume 15
- Issue 1
Information Age Audits
by Joseph F. Noferi, Daniel E. Worden, and Edward R. Arling Understanding the reach of 21 CFR Part 11 is the first step to assessing its impact. To protect your company, you need integrated quality audit solutions to evaluate the underlying validation of your electronic data.
Advertisement
Articles in this issue
over 23 years ago
Inside Washington: Biotechnology in the Limelight, the Year Aheadover 23 years ago
Your Vested Interests: The War of the Westover 23 years ago
Statistics for Laboratory Method Comparison Studiesover 23 years ago
Liposomes (a Review): Part Two, Drug Delivery SystemsNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
2
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
3
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
4
Selecting the Right Drug Delivery Formulations to Enhance Patient-Centric Care
5
